Hovione is a leading CDMO in dry powder formulations for Inhalation and Nasal, leveraging from our expertise in Particle Engineering and its integration into Drug Product.

One of our core approaches is the use of in silico modeling to support formulation design and predict outcomes prior to any experimentation. We use the same technology and fundamental principles in early development as will be used in late stage, allowing us to establish a formulation process around scale-independent parameters and obtain safe, effective and quality products in a lean way.
Leveraging from a collaboration driven relationship with our external technology suppliers, we are continuously adapting our formulation strategies. We acknowledge the relevance of choosing the right formulation platform, excipient and capsule at early stage. 

For inhalation drug development, our particle engineering expertise allows the formulation development of traditional composite particles suitable for small molecules or biologics. Additionally, our comprehensive and versatile platforms offer unique solutions for pharmaceutical companies seeking to develop and optimize their inhalation drug products, particularly on the high drug load range:

Related to nasal delivery, powder formulations present several advantages over liquid dosage forms due to increased stability and residence time on nasal mucosa, with improved bioavailability. For developing a robust nasal powder formulation particle engineering plays a pivotal role and the adequate formulation platform should be chosen for an efficient delivery, at minimal doses. Hovione experts can support the choice and development of the right formulation and process to manufacture particles with such particular characteristics.

Additionally, we offer a broad range of simple, patented and globally competitive DPI devices according to target use and dose - from single to multi-use inhalers for both pulmonary and nasal (including nose-to-brain) therapeutic indications, seamlessly integrated with our formulation development capabilities.

Our state-of-the-art development methodology includes

• Spray drying of small molecules and biopharmaceuticals for orally inhaled and nasal products, from low to high doses
• Particle engineering by jet milling and wet polishing
• Formulation platforms for high dose and high efficiency inhalation delivery
• High and low shear blending for standard and high dose carrier-based formulations for inhalation delivery
• Seamless integration between formulation and device development

Contact our experts today.

Hovione offers proven and innovative scientific expertise, that provides solutions to your complex challenges.

Learn more with the following webinar by Hovione's experts:

• High performance solutions for DPI Delivery
• Nasal powder delivery: Process, formulation and analytical characterization (available soon)